A Real World Study for the Efficacy and Safety of Large Dose Tanreqing Injection in the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19)
Phase 4
- Conditions
- novel coronavirus pneumonia (COVID-19)
- Registration Number
- ITMCTR2000002948
- Lead Sponsor
- The First Afflicated Hospital of Guangzhou University of Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1. Confirmed or suspected cases who are comply with the diagnostic criteria for pneumonia caused by novel coronavirus infection in the Diagnosis and Treatment Program for pneumonia caused by novel coronavirus infection (Trial Version 4);
2. Inpatients aged 18-75 years;
3. Obtain the informed consent form.
Exclusion Criteria
1. Patients with severe novel coronavirus pneumonia;
2. Patients with severe basic diseases;
3. Patients who have mental confusion, pregnant or lactating women, who with a history of drug abuse or dependence, who allergic to study medication, who have participated in another clinical trial within 3 months,or who have other conditions not suitable for clinical study.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Chest X-ray absorption;Time for body temperature recovery;
- Secondary Outcome Measures
Name Time Method Biochemical Indicators;Routine blood test;Procalcitonin;Liver and renal function;C-reactive protein;Heart enzyme index;Blood gas analysis;